Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma

NCT02107755 is registered in ClinicalTrials.gov with Ohio State University Comprehensive Cancer Center as lead sponsor.

NCT NCT02107755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma
Lead sponsor
Ohio State University Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2014
Completion date
August 16, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, lung metastases, recurrent melanoma, stage iv melanoma, tumors metastatic to brain